FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094745505> ?p ?o ?g. }

• W3094745505 endingPage "472" @default.
• W3094745505 startingPage "460" @default.
• W3094745505 abstract "This phase I/IIa study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist IgG1 mAb, ± nivolumab and/or ipilimumab in patients with advanced solid tumors.Patients (with non-small cell lung, renal cell, bladder, other advanced cancers) received BMS-986178 (20-320 mg) ± nivolumab (240-480 mg) and/or ipilimumab (1-3 mg/kg). The primary endpoint was safety. Additional endpoints included immunogenicity, pharmacodynamics, pharmacokinetics, and antitumor activity per RECIST version 1.1.Twenty patients received BMS-986178 monotherapy, and 145 received combination therapy in various regimens (including two patients receiving nivolumab monotherapy). With a follow-up of 1.1 to 103.6 weeks, the most common (≥5%) treatment-related adverse events (TRAEs) included fatigue, pruritus, rash, pyrexia, diarrhea, and infusion-related reactions. Overall, grade 3-4 TRAEs occurred in one of 20 patients (5%) receiving BMS-986178 monotherapy, six of 79 (8%) receiving BMS-986178 plus nivolumab, zero of two receiving nivolumab monotherapy, six of 41 (15%) receiving BMS-986178 plus ipilimumab, and three of 23 (13%) receiving BMS-986178 plus nivolumab plus ipilimumab. No deaths occurred. No dose-limiting toxicities were observed with monotherapy, and the MTD was not reached in either the monotherapy or the combination escalation cohorts. No objective responses were seen with BMS-986178 alone; objective response rates ranged from 0% to 13% across combination therapy cohorts.In this study, BMS-986178 ± nivolumab and/or ipilimumab appeared to have a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab." @default.
• W3094745505 created "2020-11-09" @default.
• W3094745505 creator A5006299989 @default.
• W3094745505 creator A5009935310 @default.
• W3094745505 creator A5010044441 @default.
• W3094745505 creator A5012217813 @default.
• W3094745505 creator A5015994964 @default.
• W3094745505 creator A5019947750 @default.
• W3094745505 creator A5022339242 @default.
• W3094745505 creator A5029243551 @default.
• W3094745505 creator A5037530844 @default.
• W3094745505 creator A5042192155 @default.
• W3094745505 creator A5052985668 @default.
• W3094745505 creator A5069558511 @default.
• W3094745505 creator A5070812231 @default.
• W3094745505 creator A5076736008 @default.
• W3094745505 creator A5082061757 @default.
• W3094745505 creator A5084448096 @default.
• W3094745505 creator A5084722844 @default.
• W3094745505 creator A5085499011 @default.
• W3094745505 creator A5086473468 @default.
• W3094745505 creator A5088186975 @default.
• W3094745505 date "2021-01-15" @default.
• W3094745505 modified "2023-10-13" @default.
• W3094745505 title "OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors" @default.
• W3094745505 cites W1837454186 @default.
• W3094745505 cites W1913188064 @default.
• W3094745505 cites W1990013942 @default.
• W3094745505 cites W1992546156 @default.
• W3094745505 cites W1992979622 @default.
• W3094745505 cites W2019607817 @default.
• W3094745505 cites W2095699174 @default.
• W3094745505 cites W2104578054 @default.
• W3094745505 cites W2106605927 @default.
• W3094745505 cites W2118486765 @default.
• W3094745505 cites W2118546263 @default.
• W3094745505 cites W2134435470 @default.
• W3094745505 cites W2142943268 @default.
• W3094745505 cites W2166662937 @default.
• W3094745505 cites W2189381691 @default.
• W3094745505 cites W2209812019 @default.
• W3094745505 cites W2344741754 @default.
• W3094745505 cites W2398545566 @default.
• W3094745505 cites W2519279652 @default.
• W3094745505 cites W2560704457 @default.
• W3094745505 cites W2589045559 @default.
• W3094745505 cites W2703678370 @default.
• W3094745505 cites W2741119937 @default.
• W3094745505 cites W2747769029 @default.
• W3094745505 cites W2753944720 @default.
• W3094745505 cites W2792937256 @default.
• W3094745505 cites W2794675189 @default.
• W3094745505 cites W2807748927 @default.
• W3094745505 cites W2886825992 @default.
• W3094745505 cites W2891308638 @default.
• W3094745505 cites W2891798109 @default.
• W3094745505 cites W2903685741 @default.
• W3094745505 cites W2930574992 @default.
• W3094745505 cites W2967447726 @default.
• W3094745505 cites W2970873072 @default.
• W3094745505 cites W2972242424 @default.
• W3094745505 cites W2978136097 @default.
• W3094745505 cites W3049304916 @default.
• W3094745505 cites W4242982114 @default.
• W3094745505 doi "https://doi.org/10.1158/1078-0432.ccr-20-1830" @default.
• W3094745505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33148673" @default.
• W3094745505 hasPublicationYear "2021" @default.
• W3094745505 type Work @default.
• W3094745505 sameAs 3094745505 @default.
• W3094745505 citedByCount "40" @default.
• W3094745505 countsByYear W30947455052021 @default.
• W3094745505 countsByYear W30947455052022 @default.
• W3094745505 countsByYear W30947455052023 @default.
• W3094745505 crossrefType "journal-article" @default.
• W3094745505 hasAuthorship W3094745505A5006299989 @default.
• W3094745505 hasAuthorship W3094745505A5009935310 @default.
• W3094745505 hasAuthorship W3094745505A5010044441 @default.
• W3094745505 hasAuthorship W3094745505A5012217813 @default.
• W3094745505 hasAuthorship W3094745505A5015994964 @default.
• W3094745505 hasAuthorship W3094745505A5019947750 @default.
• W3094745505 hasAuthorship W3094745505A5022339242 @default.
• W3094745505 hasAuthorship W3094745505A5029243551 @default.
• W3094745505 hasAuthorship W3094745505A5037530844 @default.
• W3094745505 hasAuthorship W3094745505A5042192155 @default.
• W3094745505 hasAuthorship W3094745505A5052985668 @default.
• W3094745505 hasAuthorship W3094745505A5069558511 @default.
• W3094745505 hasAuthorship W3094745505A5070812231 @default.
• W3094745505 hasAuthorship W3094745505A5076736008 @default.
• W3094745505 hasAuthorship W3094745505A5082061757 @default.
• W3094745505 hasAuthorship W3094745505A5084448096 @default.
• W3094745505 hasAuthorship W3094745505A5084722844 @default.
• W3094745505 hasAuthorship W3094745505A5085499011 @default.
• W3094745505 hasAuthorship W3094745505A5086473468 @default.
• W3094745505 hasAuthorship W3094745505A5088186975 @default.
• W3094745505 hasBestOaLocation W30947455051 @default.
• W3094745505 hasConcept C111113717 @default.
• W3094745505 hasConcept C112705442 @default.
• W3094745505 hasConcept C121608353 @default.

• next